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1. Introduction 
The standard treatment for early breast cancer is breast-conserving therapy (BCT) with 
whole breast external irradiation therapy (WBI), and local control plays crucial role on 
survival (Clarke et al., 2005). It has been established that there is no significant difference 
in disease-free or overall survival rates between treatment by mastectomy or by 
lumpectomy with WBI for women with early breast cancer (Fisher et al., 2002; Veronesi et 
al., 2002). WBI actually provides statistically significant local control and survival data out 
to 15 years in favor of WBI compared to none (Clarke, et al., 2005). In actuality many 
women are still encouraged to proceed to mastectomy, because of the lack of access to 
radiotherapy centers or the long course of treatment of WBI. On the other hand, local 
recurrences after BCT with or without WBI arise most in the same quadrant as the 
primary cancer (Veronesi et al., 2001). The main objective of radiotherapy after BCT is 
considered to be the destruction of residual cancer cells in the operative field. Partial 
breast irradiation (PBI) has been tested in clinical trials for selected patients, and these 
studies have shown adequate local control, minimal toxicity, and good cosmetic 
appearance (Njeh et al., 2010). Intraoperative radiotherapy (IORT) is one of these PBI 
methods, which has recently been used in early stage breast cancer. Partial breast 
radiation therapy administered around the tumor bed has been comparable to WBI in 
selected patients (Antonucci et al., 2009; Benitez et al., 2007; Vicini et al., 2001; Vicini et al., 
2003). Many phase II or III trials evaluating adjuvant IORT are actively accruing patients 
in the United States (NSABP-B39), Europe, United Kingdom, and Australia (Holmes et al., 
2007). The standard treatment for early breast cancer is BCT with WBI, and outside the 
setting of a clinical trial, use of IORT as well as accelerated partial breast irradiation 
(APBI) is not yet recommended (Njeh, et al., 2010; Skandarajah et al., 2009). Then, 
particularly in practice setting, patients’ selection is critical to the successful application of 
PBI (Polgár et al., 2010; Vicini et al., 2011). 
This review concentrates on the eligibility, methods, outcome, and the point at issue of IORT 
for early breast cancer. With regard to terms, I defined IORT as the delivery of single 
fractional dose irradiation directly to the tumor bed during operation, and PBI as irradiation 
confined to the tumor bed either during operation or after surgery. 
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2. Eligibility for IORT – Who is suitable for IORT? 
Many attempts have been made to identify subgroups of patients who might avoid 
radiotherapy after BCT, but these are not distinct factors. In general, the risk factors for local 
recurrence after BCT are larger tumor size, higher tumor grade, younger age, lymph node-
positive, and close surgical margin (Clarke, et al., 2005; Fisher, 1997; Park et al., 2000). Then, 
we review clinical questions of which patients can be considered for IORT. Some points are 
discussed separately as below. 
2.1 Age 
Cumulative incidence of recurrence of tumor in the ispilateral breast after WBI with a boost 
is different among age, younger women have higher incidence (Bartelink et al., 2007). Age ≥ 
50 years has been selected in most prospective trials, and studies have shown that elderly 
patients treated with WBI (Antonini et al., 2007; Bartelink, et al., 2007) or MammoSite® 
(Chao et al., 2007) were low risk. Few women younger than 50 has been treated with PBI in 
prospective single arm studies. 
2.2 Tumor size 
A maximum tumor size of 2cm has been selected in most prospective trials. T2 tumors 
(>2cm, ≤5cm) or T0 (ductal carcinoma in situ; DCIS) tumors are cautionary recommended 
(Smith et al., 2009). Patients with T3 or T4 tumors should not receive PBI. An extensive 
intraductal component should be treated with caution. Patients with multicentric tumors; 
i.e. presence of foci of cancer in different quadrants, should not receive PBI because of the 
extent of disease. Patients of clinically unifocal or multifocal tumors with a total tumor size 
no greater than 2 cm could be suitable for PBI (Smith, et al., 2009). 
2.3 Nodal status 
Node positive is one of the risk factor for ispilateral breast cancer (Clarke, et al., 2005). Then, 
majority of patients who have been treated in prospective single arm APBI trials had 
pathologically node negative disease. Patients who do not undergo surgical nodal 
assessment or who have pathologic evidence of nodal involvements should not receive PBI. 
2.4 Pathology 
One area of concern in the use of IORT is the management of positive surgical margins as 
positivity is discovered at the final histology, a few days after surgery and IORT. Attention 
should be paid to ensure negative margins on final pathology (Beal et al., 2007), although 
margin positivity does not always influence the rate of local recurrences if effective 
radiotherapy is delivered (Chism et al., 2006; Mariani et al., 1998; Veronesi et al., 2010). 
Intraoperative frozen sections may be used to reduce positive margins (Fukamachi et al., 
2010). Patients with close but negative margins (<2 mm) may be treated with caution (Smith, 
et al., 2009). Tumors with higher tumor grade is not suitable for PBI, because it is one of risk 
factors for local recurrence and most prospective trials have not considered as eligibility 
criteria. As for the tumor characteristics biologically, such as HER2-type or basal-type have 
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been shown to involve higher risk for local recurrence than luminal A or B-types (Kyndi et 
al., 2008; Nguyen et al., 2008; Veronesi, et al., 2010), then tailored local-regional treatment for 
early-stage breast cancer has been reported to be mandatory now (Solin, 2010). 
2.5 Oncology 
There has been only limited study of IORT including PBI in patients receiving neoadjuvant 
or concurrent chemotherapy. For patients who will receive adjuvant chemotherapy, it is 
recommended that APBI be performed first and that there should be an interval of at least 2 
to 3 weeks between completion of APBI and initiation of chemotherapy (Smith, et al., 2009). 
Thus, IORT including PBI allows radiotherapy to be given without delaying administration 
of chemotherapy or hormonal therapy. But careful observation is needed; a retrospective 
analysis from MammoSite registry single arm trial reported an association between 
initiation of adjuvant chemotherapy within 3 weeks of the last MammoSite treatment and an 
increased risk of both radiation recall skin retraction and suboptimal cosmetics (Haffty et al., 
2008). There is no data when adjuvant endocrine therapy with APBI should be started. 
We show recommendation for APBI in Table 1. 
 
Factors Suitable group 
 Age ≥60 
 BRCA1/2 mutation Not present 
 Tumor size ≤2 cm 
 T stage T1 
 Margins Negative by at least 2 mm 
 Grade Any 
 LVSI No 
 ER statis Positive 
 Multicentricity Unicentric only 
 Mutifocally Clinically unifocal with total size ≤2 cm 
 Histology Invasive ductal or other favorable subtypes 
 Pure DCIS Not allowed 
 EIC Not allowed 
 Associated LCIS Allowed 
 Nodal status pN0 
 Nodal surgery SN Bx or ALND 
 Neoadjuvant Therapy Not allowed 
Table 1. Suitable patient group recommendation selections for APBI outside of clinical trials; 
ASTRO Consensus Statement (Smith, et al., 2009) 
3. Radiation methods 
Several radiation methods are commonly in use for IORT. We show various radiation 
techniques for IORT in Table 2. 
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Author Year 
(publish) 
No. of 
cases 
Median 
follow up 
(months) 
Technique Ispilateral breast cancer 
recurrence (%) 
Sawaki M  2011 32 26 Electrons 0 
Veronesi U  2010 1,822 36.1 Electrons 1.3 
Vaidya JS  2010 854 48 Photons 1.2 
Lemanski C  2010 42 30 Electrons 4.8 
Mussari S  2006 47 48 Electrons 0 
Table 2. Clinical studies using full-dose Intraoperative radiation therapy (IORT) 
3.1 Electrons Intraoperative Therapy (ELIOT) 
3.1.1 As a single fractional dose 
ELIOT is one of these PBI methods, which has recently been used in early stage breast 
cancer, mainly at the European Institute of Oncology (Italian: Istituto Europeo di Oncologia; 
IEO) in Milan since 1999 (Intra et al., 2006; Luini et al., 2005; Veronesi et al., 2005; Veronesi, 
et al., 2010; Veronesi et al., 2001). They have been promoted to prospective trials to 
investigate tolerance to increased IORT doses and ultimately to introduce the use of 21 Gy in 
the context of breast conserving surgery. A single dose of 21 Gy at 90% isodose has been 
shown to be feasible in European breast cancer patients and biologically equivalent to a full 
dose of conventional WBI (Intra, et al., 2006; Luini, et al., 2005; Veronesi, et al., 2005; 
Veronesi, et al., 2001). The main advantages are follows. 1) To be able to deliver the 
radiation before tumor cells have a chance to proliferate under surgical intervention have a 
rich vascularization, which makes them more sensitive to the action of the radiation. 2) To 
be able to deliver under direct visualization at the time of surgery. It has the potential for 
accurate dose delivery by permitting delivery of the radiation dose directly to the surgical 
margins. 3) IORT could minimize some potential side effects, since skin and the 
subcutaneous tissue can be displaced. 4) The spread of irradiation to lung and heart is 
reduced significantly. 5) IORT allows radiotherapy to be given without delaying 
administration of chemotherapy or hormonal therapy. 6) There is potential for decreasing 
healthcare cost, because it is one fraction as opposed to 25 fractions. For elderly patients, it is 
feasible and corresponded to acceptable quality index criteria (Lemanski et al., 2010). In 
Asian breast cancer patients 21 Gy was recommended as a result of phase I study, which had 
been used a scheme of dose-escalation from 19, 20, and 21 Gy. (Sawaki et al., 2009), and 
subsequent phase II study indicated feasibility at 21 Gy (Sawaki et al., 2011). In this technique a 
disk should be needed to reduce the spread of irradiation to lung and heart. The disk is located 
between gland and pectoralis muscle. The aluminum and lead disk has been used in Italy 
(Intra, et al., 2006; Mussari et al., 2006). As for an another kind of disk, two layers disk; a first 
layer (source side) of polymethyl methacrylate (PMMA) and a second layer of copper was 
designed and selected from metals such as aluminum, copper and lead after testing for their 
shielding capabilities and the range of the backscatter (Oshima et al., 2009). 
IORT extends the primary operation only for an additional 15 minutes plus approximately 
30 minutes of a radiotherapy physicist’s time to prepare the device(Sawaki, et al., 2009), 
although conventional WBI radiotherapy usually requires 5 weeks of outpatient treatment. 
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The largest randomized clinical trial to date is now in progress at the Milan Institute. The 
goal of the trial is to determine the equivalence of local recurrence rates between 
quadrantectomy with conventional WBI and that with IORT. To date, they remain 
investigational until information on its long-term efficacy and safety becomes available 
(Buchholz, 2009). In the trial at the Milan Institute, 21 Gy, which is recommended through 
more than 1000 IORT procedures (Intra, et al., 2006), was used for the IORT arm. In the most 
update data, local recurrence rate was 1.3% (24/1,822) (Veronesi, et al., 2010). In addition, 
IORT can achieve early initiation of radiotherapy (RT). Delay in the initiation of RT is 
associated with a decrease in local recurrence rate (Huang, 2003). 
3.1.2 As a boost 
With regard to another concept of full-dose intraoperative radiotherapy, an anticipated 
boost during operation has been studied (Reitsamer et al., 2002; Reitsamer et al., 2006). A 
single dose of 9 Gy was applied to the 90% reference isodose with energies ranging from 4 
to 15 MeV, using round applicator tubes 4–8 cm in diameter. After wound healing, the 
patients received additional 51 – 56 Gy external boost radiation (EBRT) to the whole breast 
(Reitsamer, et al., 2002). The advantages are follows. 1) To complete skin sparing, 2) the 
precise application of the boost directly to the tumor bed with a homogeneous tissue 
radiation and 3) to reduce postoperative radiation time for 7-10 days (time of postoperative 
boost radiotherapy) (Reitsamer, et al., 2002; Reitsamer, et al., 2006). 
3.1.3 Nipple sparing mastectomy 
Nipple sparing mastectomy can be applied for treatment of breast cancer when mastectomy 
is indicated. To reduce the risk of retro areolar recurrence, radio-surgical treatment 
combining subcutaneous mastectomy with intraoperative radiotherapy (ELIOT) is proposed 
(Petit et al., 2009; Petit et al., 2009). The IORT with electrons of 16 Gy in one shot was 
delivered on the nipple areolar area. Local recurrence rate was not higher than the usual rate 
observed in the literature, although longer follow up is needed. 
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Fig. 1. Intraoperative radiotherapy (electrons) 
3.2 Targeted intraoperative radiotherapy (TARGIT) 
This device is inserted intraopetatively into the tumor cavity after excision of the tumor and 
emits X-rays from within the breast (Vaidya et al., 2010). The authors used a miniature 
electron-beam-driven X-ray source called Intrabeam®, which emits low energetic X-rays 
with 50 kV from the point source. In large randomized clinical trial, TARGIT trial for 
selected patients with early breast cancer, a single dose of radiotherapy delivered at the time 
of surgery by use of targeted intraoperative radiotherapy is considered as an alternative to 
external beam radiotherapy delivered over several weeks (Vaidya, et al., 2010), although it 
needs longer follow up to conclude the no inferiority to the WBI (Reitsamer et al., 2010). 
4. Conclusion 
In conclusion, IORT is an option applied for breast conserving therapy in the selected 
patients. TARGIT trial has been considered as an alternative to external beam radiotherapy 
delivered over several weeks (Vaidya, et al., 2010). And also ELIOT appears a promising 
feature in early breast cancer treated with breast conserving surgery, reducing the exposure 
of normal tissues to radiations and shortening the radiation course from 6 weeks to one 
single session (Veronesi, et al., 2010). These clinical studies have shown adequate local 
control, minimal toxicity, and good cosmetic appearance, although a longer follow up is 
needed for the evaluation of the late side effects. In practice setting, careful management is 
needed because patients’ selection is critical to the successful application of IORT. 
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6. Acronyms and abbreviations 
ALND; Axillary lymph node dissection 
APBI; Accelerated partial breast irradiation 
ASTRO; American Society for Radiation Oncology 
BCT; Breast conserving therapy 
DCIS; Ductal carcinoma in situ 
EBRT; External boost radiation 
EIC; Extensive intraductal component 
ELIOT; Electrons intraoperative therapy 
ER; Estrogen receptor 
IORT; Intraoperative radiotherapy 
LCIS; lobular carcinoma in situ 
LVSI; Lymph-vascular space invasion 
PBI; Partial breast irradiation 
PMMA; polymethyl methacrylate 
RT; Radiotherapy 
SN Bx; Sentinel lymph node biopsy 
TARGIT; Targeted intraoperative radiotherapy 
WBI; Whole breast external irradiation therapy 
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